Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, ORIC Pharmaceuticals Inc’s stock clocked out at $11.32, down -3.33% from its previous closing price of $11.71. In other words, the price has decreased by -$3.33 from its previous closing price. On the day, 1.3 million shares were traded. ORIC stock price reached its highest trading level at $11.8392 during the session, while it also had its lowest trading level at $11.13.
Ratios:
To gain a deeper understanding of ORIC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.13 and its Current Ratio is at 16.13. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On July 08, 2025, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $15.
On October 31, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $20.Wells Fargo initiated its Overweight rating on October 31, 2024, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 01 ’25 when Chacko Jacob sold 53,001 shares for $12.05 per share. The transaction valued at 638,805 led to the insider holds 568,880 shares of the business.
Chacko Jacob sold 34,538 shares of ORIC for $414,750 on Sep 30 ’25. The PRESIDENT AND CEO now owns 621,881 shares after completing the transaction at $12.01 per share. On Sep 22 ’25, another insider, Chacko Jacob, who serves as the PRESIDENT AND CEO of the company, sold 125,000 shares for $10.80 each. As a result, the insider received 1,349,938 and left with 656,419 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORIC now has a Market Capitalization of 1137310080 and an Enterprise Value of 825004224.
Stock Price History:
The Beta on a monthly basis for ORIC is 1.65, which has changed by 0.17793965 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, ORIC has reached a high of $14.67, while it has fallen to a 52-week low of $3.90. The 50-Day Moving Average of the stock is 8.62%, while the 200-Day Moving Average is calculated to be 30.48%.
Shares Statistics:
It appears that ORIC traded 1.10M shares on average per day over the past three months and 1659910 shares per day over the past ten days. A total of 86.19M shares are outstanding, with a floating share count of 56.00M. Insiders hold about 42.34% of the company’s shares, while institutions hold 63.05% stake in the company. Shares short for ORIC as of 1757894400 were 9528668 with a Short Ratio of 8.65, compared to 1755216000 on 7202705. Therefore, it implies a Short% of Shares Outstanding of 9528668 and a Short% of Float of 9.94.
Earnings Estimates
The stock of ORIC Pharmaceuticals Inc (ORIC) is currently drawing attention from 11.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.29 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.29 and -$2.53 for the fiscal current year, implying an average EPS of -$1.71. EPS for the following year is -$1.71, with 11.0 analysts recommending between -$1.03 and -$2.84.
